Nose-to-brain delivery of antiglioblastoma drugs embedded into lipid nanocarrier systems: status quo and outlook

Fakhara Sabir; Ruba Ismail; Ildiko Csoka

doi:10.1016/j.drudis.2019.10.005

Nose-to-brain delivery of antiglioblastoma drugs embedded into lipid nanocarrier systems: status quo and outlook

Drug Discov Today. 2020 Jan;25(1):185-194. doi: 10.1016/j.drudis.2019.10.005. Epub 2019 Oct 17.

Authors

Fakhara Sabir¹, Ruba Ismail¹, Ildiko Csoka²

Affiliations

¹ University of Szeged, Faculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, H-6720 Szeged, Eötvös u. 6, Hungary.
² University of Szeged, Faculty of Pharmacy, Institute of Pharmaceutical Technology and Regulatory Affairs, H-6720 Szeged, Eötvös u. 6, Hungary. Electronic address: csoka@pharm.u-szeged.hu.

PMID: 31629966
DOI: 10.1016/j.drudis.2019.10.005

Abstract

Glioblastoma multiforme (GBM) is one of the most devastating and deadly types of tumor. Among all the present treatment strategies, the utmost prerequisite is prolonged intervention at the malignant site. The blood-brain barrier (BBB) is the bottleneck in the delivery of anti-GBM drugs and invasive treatment comes with many pitfalls. This review will discuss the potential of embedding antitumor drugs into nanocarriers for intranasal delivery. Additionally, it emphasizes the significance of applying quality by design (QbD) methodology from the early development stages to ensure the high quality, safety and efficacy of the developed carrier system.

Publication types

Review

MeSH terms

Administration, Intranasal
Animals
Antineoplastic Agents / administration & dosage*
Brain / metabolism*
Brain Neoplasms / drug therapy*
Brain Neoplasms / metabolism
Drug Carriers / administration & dosage*
Glioblastoma / drug therapy*
Glioblastoma / metabolism
Humans
Lipids / administration & dosage
Nanoparticles / administration & dosage*
Nasal Mucosa / metabolism*

Substances

Antineoplastic Agents
Drug Carriers
Lipids